Market news

The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how patient monitoring stocks fared in Q2, starting with iRhythm (NASDAQ:IRTC).

Opportunities center on AI-enabled wearable ECG bands, remote monitoring, point-of-care diagnostics and home use, driven by telemedicine and preventive care, especially in emerging markets. Mobile ECG Devices Market Mobile ECG Devices Market Dublin, Sept. 02, 2026 (GLOBE NEWSWIRE) -- The "Mobile ECG Devices Global Market Opportunities and Strategies to 2035" has been added to ResearchAndMarkets.com's offering. The global mobile ECG devices market is experiencing strong growth as healthcare provi

SAN FRANCISCO, Aug. 26, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced that it will...

iRhythm Holdings (IRTC) informed investors that Board member and Audit Committee chair Brian Yoor resigned for personal reasons on August 12, 2026. Existing director Karen McGinnis will step in to chair the Audit Committee. iRhythm Holdings’ share price has been volatile over 2026, with a 30 day share price return of 12.72% and a 7 day gain of 6.81%. However, the year to date share price return is down 29.75% and the 1 year total shareholder return is down 26.74%, even though the 5 year total...

Detailed price information for Irhythm Holdings Inc (IRTC-Q) from The Globe and Mail including charting and trades.

Detailed price information for 4D Molecular Therapeutics Inc (FDMT-Q) from The Globe and Mail including charting and trades.

iRhythm’s second quarter results were met with a strong positive market reaction, reflecting the company’s ability to deliver both robust revenue growth and significant margin improvement. Management attributed this performance to sustained demand for the Zio ambulatory cardiac monitoring platform and effective commercial execution across cardiology, primary care, and new healthcare channels. CEO Quentin Blackford noted that the company’s operational discipline and successful integration of digi

IRTC's VitalConnect deal expands its cardiac monitoring reach across ambulatory, inpatient and hospital-to-home care while opening new growth opportunities.

Tipranks Press Release.

Detailed price information for Irhythm Holdings Inc (IRTC-Q) from The Globe and Mail including charting and trades.

Detailed price information for Irhythm Holdings Inc (IRTC-Q) from The Globe and Mail including charting and trades.

Shares of medical technology company iRhythm Technologies (NASDAQ:IRTC) fell 2.8% in the afternoon session after a significant price target cut from an analyst overshadowed the company's strong quarterly earnings report.

Detailed price information for Irhythm Holdings Inc (IRTC-Q) from The Globe and Mail including charting and trades.

Detailed price information for Irhythm Holdings Inc (IRTC-Q) from The Globe and Mail including charting and trades.

iRhythm (IRTC) could benefit from stronger sales growth, wider access to the cardiac monitoring mark

IRTC posts 20.1% revenue growth, margin expansion and a higher 2026 outlook while advancing innovation and its Vital Connect acquisition.

Acquiring VitalConnect could unlock a $1 billion cardiac monitoring market that is only partly served by iRhythm’s existing devices.

Medical technology company iRhythm Technologies (NASDAQ:IRTC) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 20.1% year on year to $224.2 million. The company expects the full year’s revenue to be around $885 million, close to analysts’ estimates. Its non-GAAP profit of $0.58 per share was significantly above analysts’ consensus estimates.

Detailed price information for Irhythm Holdings Inc (IRTC-Q) from The Globe and Mail including charting and trades.

Detailed price information for Irhythm Holdings Inc (IRTC-Q) from The Globe and Mail including charting and trades.

Detailed price information for Irhythm Holdings Inc (IRTC-Q) from The Globe and Mail including charting and trades.

Detailed price information for Irhythm Holdings Inc (IRTC-Q) from The Globe and Mail including charting and trades.

iRhythm Technologies (IRTC) has an average rating of buy and mean price target of $176.86, according

iRhythm to acquire VitalConnect for $287.5 million, expands cardiac monitoring portfolio after Q2 earnings beat and higher fiscal 2026 guidance.

iRhythm Holdings (IRTC) stock rises as the company posts better-than-expected Q2 2026 financials and announces a $287.5M deal to buy Vital Connect. Read more here.

IRhythm announced the deal alongside its Q2 financials in which its revenues rose 20.1% YoY.

IRHYTHM HLDGS (IRTC) delivered earnings and revenue surprises of +5,900.00% and +2.18%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Detailed price information for Irhythm Holdings Inc (IRTC-Q) from The Globe and Mail including charting and trades.

iRhythm Technologies (NASDAQ:IRTC) reported second-quarter revenue growth of 20.1% and raised its full-year outlook, while announcing an agreement to acquire VitalConnect to broaden its cardiac monitoring portfolio and enter additional patient-monitoring markets. Revenue for the quarter ended at $2

Detailed price information for Irhythm Holdings Inc (IRTC-Q) from The Globe and Mail including charting and trades.

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q1. Today, we are looking at patient monitoring stocks, starting with iRhythm (NASDAQ:IRTC).